Momelotinib

Chemical formula: C₂₃H₂₂N₆O₂  Molecular mass: 414.18 g/mol  PubChem compound: 25062766

Therapeutic indications

Momelotinib is indicated for:

Splenomegaly in primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis

Population group: only adults (18 years old or older)

Momelotinib is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Momelotinib is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Active infection

Infectious disease

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2023: OJJAARA Tablet
Summary of Product Characteristics (SPC) 2024: OMJJARA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈